Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III
Second Drug Is Market’s First Intranasal CGRP Inhibitor
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.
